Full Press Release Details
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525.
IMMP
Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Key Takeaway: Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525
Price reaction · baseline $3.64 (2021-08-25 close) · hit after-hours · 3 other IMMP headline(s) in the window, move may be shared
day 0 close · peak
-0.8%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+76%
120-day peak, hindsight
Typical move
5.4%
average across 13 past catalysts
Lead asset
eftilagimod alfa
Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)